Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604289 · ClinicalTrials.gov registry record · Early Phase 1
Angiotensin 1-7 in Obesity Hypertension
A Early Phase 1 study, sponsored by Amy Arnold.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03604289: Clinical Trial Early Phase 1 study, sponsored by Amy Arnold.
NCT03604289 is a Early Phase 1 study that was terminated before completion, run by Amy Arnold. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03604289, a Early Phase 1 study, was terminated before completion, sponsored by Amy Arnold.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2023-06-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604289
The ClinicalTrials.gov registry entry for NCT03604289 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amy Arnold, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT03604289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03604289 about?
NCT03604289 is a clinical study titled "Angiotensin 1-7 in Obesity Hypertension". The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.
What is the current status of trial NCT03604289?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-04-01. Estimated completion is 2023-06-03.
What interventions are being tested in trial NCT03604289?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT03604289?
This trial is sponsored by Amy Arnold, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.